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Abstract 79 
Objectives 80 
Drug product performance in patients with gastrointestinal (GI) diseases can be altered 81 
compared to healthy subjects due to pathophysiological changes. In this review relevant 82 
differences in patients with inflammatory bowel diseases, celiac disease, irritable bowel 83 
syndrome and short bowel syndrome are discussed and possible in vitro and in silico tools to 84 
predict drug product performance in this patient population are assessed.   85 
Key findings 86 
Drug product performance was altered in patients with GI diseases compared to healthy 87 
subjects, as assessed in a limited number of studies for some drugs. Underlying causes can be 88 
observed pathophysiological alterations such as the differences in GI  transit time, the 89 
composition of the GI fluids and GI permeability. Additionally, alterations in the abundance of 90 
metabolising enzymes and transporter systems were observed. The effect of the GI diseases on 91 
each parameter is not always evident as it may depend on the location and the state of the 92 
disease. The impact of the pathophysiological change on drug bioavailability depends on the 93 
physicochemical characteristics of the drug, the pharmaceutical formulation and drug 94 
metabolism. In vitro and in silico methods to predict drug product performance in patients with 95 
GI diseases are currently limited but could be a useful tool to improve drug therapy.  96 
Conclusions 97 
Development of suitable in vitro dissolution and in silico models for patients with GI diseases 98 
can improve their drug therapy. The likeliness of the models to provide accurate predictions 99 
depends on the knowledge of pathophysiological alterations and thus, further assessment of 100 
physiological differences is essential.   101 
5 
 
1. Introduction 102 
Oral drug absorption is a very complex process which is dependent on the physiological 103 
conditions in the gastrointestinal (GI) tract, the pharmaceutical formulation and the 104 
physicochemical characteristics of the drug. [1] Pharmacokinetic properties of drugs often 105 
display high variability in a healthy population group and pathophysiological changes in 106 
patients with GI diseases can further intensify this variability and affect drug product 107 
performance. [2] 108 
Patients suffering from GI diseases take a variety of medicines not only for the GI condition 109 
but also for concomitant conditions. Differences in the bioavailability of drugs due to the GI 110 
disease state can provoke sub-therapeutic or toxic levels of drugs and therefore, have an impact 111 
on the safety and efficacy of drug therapy. [3]  112 
Differences in the pharmacokinetics of orally administered drugs between healthy subjects 113 
(controls) and patients with GI diseases have been observed .[4; 5] Careful interpretation is 114 
needed, as some of these studies are poorly controlled, include only a small patient population 115 
and study findings are conflicting. Various physiological factors affecting drug absorption can 116 
be altered in GI disease states. Differences in GI transit time and hydrodynamics influence the 117 
passage of the drug and formulation through the GI compartments.[6; 7] Changes in the 118 
composition and characteristics of GI fluids such as bile salt concentrations, pH and osmolality 119 
can affect the drug release from formulations and the solubilisation of the drug.[8] Alterations 120 
of the GI membranes and dissimilar expression of transporter systems can affect drug 121 
permeability.[9] Differences in the expression pattern of metabolic enzymes in the GI membrane 122 
can influence the intestinal first pass metabolism.[8] Alterations in the composition and the 123 
location of the GI microbiota can change the exposure of drugs and formulations to bacterial 124 
enzymes and may therefore change the metabolism or release of the drug respectively.[10; 11] 125 
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To enable prediction of the in vivo performance of drug products in healthy adults the use of in 126 
vitro dissolution methods and in silico models has been established.[12; 13] Knowledge of the 127 
pathophysiological GI conditions can improve the design of in vitro and in silico models, 128 
improve the ability to predict the drug product performance in patients with GI diseases and 129 
facilitate the development of suitable formulations to enhance drug efficacy.  130 
The current review gives an overview of altered GI conditions in patients with inflammatory 131 
bowel disease (IBD), celiac disease, irritable bowel syndrome (IBS) and short bowel syndrome 132 
(SBS). The consequences of these disease states on drug absorption are analysed. Finally, the 133 
suitability of existing in vitro dissolution and in silico models to predict the drug product 134 
performance in patients with GI diseases is critically discussed. 135 
2. Physiological alterations in GI diseases affecting absorption 136 
2.1. Inflammatory bowel diseases 137 
2.1.1. General information 138 
IBD is a recurrent or continuous inflammation of the bowel. Numerous factors (environmental, 139 
microbial and genetic) contribute to IBD while its aetiology remains still unknown.[14] In the 140 
US 1.4 million people suffer from IBD and 396 per 100 000 persons worldwide.[8] The 141 
prevalence of IBD is constantly rising. It is higher in northern, industrialized countries and 142 
emerges in newly industrialized countries.[15; 16] The two main forms of IBD are Crohn’s 143 
disease (CD) and ulcerative colitis (UC). Numerous alterations in the GI physiology of IBD 144 
patients (e.g. mucosal lesions, thickened bowel wall and strictures) may influence drug 145 
absorption.[17] 146 
2.1.1.1. Ulcerative colitis 147 
UC is a continuous uniform inflammation of the colon and rectum with periods of relapse and 148 
remission. Typically, the inflammation spreads from the rectum/ descending colon to the 149 
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acending colon. Depending on the affected area and extent of the disease it can be grouped into 150 
ulcerative proctitis, left-side colitis, sub-total colitis and pancolitis.[18] The diffuse 151 
inflammation involves only the mucosa and submucosa which appear granular and 152 
haemorrhagic. During active disease UC histology reveals neutrophil-mediated damaged 153 
epithelium.[19] This includes cryptitis, crypt abscesses where the lumen is filled with 154 
neutrophils and debris, and mucosal ulceration.[19] As the disease progresses, neutrophils 155 
infiltrate the lamina propria, crypts get shorter and branched and Paneth cells occur in the left 156 
colon.[19] The typical clinical manifestation of UC includes chronic diarrhoea with blood in the 157 
stool.[20]  158 
2.1.1.2. Crohn’s disease 159 
The second type of IBD is CD. CD can affect the entire GI tract from mouth to anus, often 160 
discontinously, but is most likely to occur in the terminal ileum or ascending colon.[21] Initially 161 
the disease is limited to the submucosa which appears red and swollen due to lymphoid 162 
hyperplasia and lymphedema.[22] In a later stage, the disease extends transmurally and involves 163 
the full thickness of the GI wall.[21; 22] Endoscopic examination of CD patients reveals cobble-164 
stoning mucosa and linear or aphthous ulcers with a haemorrhagic rim form. Radiological 165 
findings in CD typically illustrate ileac involvement, fistulas and asymmetric manifestation. 166 
The classic clinical presentation of CD involves diarrhoea and recurrent abdominal pain. Other 167 
symptoms include abdominal cramps, fever, malaise and weight loss. CD complications 168 
include malabsorption, bowel obstruction, strictures, crypt abscesses and fistulas.[22] 169 
2.1.2. Gastrointestinal transit time/motility and pH 170 
2.1.2.1. Ulcerative colitis 171 
GI transit time varies between healthy adults and patients with ulcerative colitis (Table 1). 172 
Different results considering the total gastrointestinal transit time (TGTT)  have been 173 
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published. TGTT was strongly increased in patients with UC and this finding was even more 174 
pronounced in patients in remission compared to patients with severe disease.[23; 24] Similar 175 
TGTT to controls has been observed in one study possibly attributed to the methodology (large 176 
size of the telemetery capsule).[25] UC patients with severe disease have shown high variability 177 
in TGTT.[26]  178 
Gastric residence time  in the fed state was slightly prolonged in UC patients but this was not 179 
statistically significant.[23; 27] In the fasted state, patients with UC have shown similar gastric 180 
residence times as controls.[26] Small intestinal transit times were slightly prolonged (0.2h-1.3h) 181 
in UC patients compared to controls as confirmed by a prolonged orocecal transit time as 182 
monitored using the lactulose breath test.[23; 24; 27-30]  183 
Colonic transit times measured with a telemetry capsule were increased in patients with UC, 184 
mainly due to a prolonged residence time in the middle and distal colon.[23; 28] However, 185 
decreased colonic transit times were also observed which could be attributed to the mild disease 186 
state.[27] The range of colonic transit times in healthy volunteers is 7h to 20h whereas a much 187 
wider range (2h to 97.7h) was observed for patients with very active UC consistent with high 188 
variability in the disease state.[13; 26] 189 
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GI motility in the jejunum and ileum as quantified by Magnetic Resonance Imaging (MRI) was 190 
not altered in patients with UC compared to controls.[34] After the intake of a meal, the colonic 191 
motility in patients with UC in remission was similar to controls.[35] Whereas the low-amplitude 192 
propagating contractions in the colon responsible for the transport of liquid contents and gases 193 
were found more often in UC patients in remission than in controls, the amount of high-194 
amplitude propagating contractions which mainly transport solid contents was similar to 195 
controls.[35] 196 
The pH profile in patients with UC was investigated in several studies (Figure 1).[25-28; 36-38] In 197 
the stomach pH was slightly higher and no major pH changes in the small intestine were 198 
observed in patients with UC compared to healthy subjects. Only the time to reach a pH of 7 199 
in the small bowel was prolonged in patients with UC compared to controls.[27] 200 
For colonic pH values conflicting results have been published (Table 2). A decrease in colonic 201 
pH was mainly observed apart from two studies in which similar or even higher pH values 202 
were detected possibly due to the individual form of the disease, the status of the inflammation 203 
process and the current treatment of the patients. 204 
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2.1.2.2. Crohn’s disease 205 
An overview over the studies investigating GI transit time in CD is given in Table 3. Gastric 206 
emptying times in patients with CD in the fed state were prolonged as measured by scintigraphy 207 
of a capsule containing 111In-labelled pellets.[40] In the fasted state, gastric emptying times in 208 
CD patients were similar to patients with different diagnosis using small capsule endoscopy 209 
studies.[40; 41] Small intestinal transit times were prolonged when measured with small capsule 210 
endoscopy studies but similar when measured by scintigraphy of labelled pellets and thus, the 211 
GI passage could be altered according to the pharmaceutical dosage form.[30; 40; 41] This finding 212 
could also be attributed to the disease state as a recent study showed that CD patients with 213 
active disease have an increased small intestinal transit time while patients with inactive disease 214 
showed similar small intestinal transit times compared to non-IBD patients.[30] Orocecal transit 215 
times were prolonged in CD patients.[29; 42] The passage through the ascending colon was not 216 
significantly different but high disease activity was linked to a shorter transit time.[40] 217 
Jejunal and ileac motility in patients with CD were similar to controls whereas terminal ileum 218 
motility was decreased.[34] Differences in bowel hydrodynamics could occur due to the 219 
thickened bowel wall in CD and as a result of strictures which hinder the passage of 220 
gastrointesinal fluids.[17] 221 
The pH profile in patients with CD was investigated in several studies (Figure 2).[25; 36; 43; 44] 222 
Patients with CD showed a tendency to higher pH in the stomach compared to controls which 223 
correlated with decreased gastric acid secretion especially when patients were malnourished 224 
(mean basal acid output: 0.64mEq/h (0.33) (malnourished), 2.12mEq/h (0.88) (nutritional 225 
support) vs. 3.85mEq/h (0.93) in controls, maximal acid output: 7.36mEq/h (1.38) 226 
(malnourished), 12.76mEq/h (2.50) (nutritional support) vs. 25.53mEq/h (4.58) in controls).[25; 227 
35; 45] Mean or median pH values in the small intestine of patients with CD were similar 228 
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compared to controls whereas the observed pH range was higher in CD patients. Similar results 229 
with more fluctuations were found for colonic pH values in CD patients with the exemption of 230 
one study with an overall mean decreased colonic pH (5.3 vs. 6.8).[25; 36; 43]  231 
2.1.3. Composition of luminal contents 232 
2.1.3.1. Ulcerative colitis 233 
The composition of the ascending colon fluid in the fasted state in UC patients in relapse and 234 
remission differed from healthy adults with elevated concentrations of soluble proteins 235 
(relapse: 18.9mg/ml (8.1), remission: 19.0mg/ml (10.8), healthy: 9.8mg/ml (4.6)) in contrast 236 
no difference in soluble carbohydrates  was observed (relapse: 5.4mg/ml (2.7), remission: 237 
6.4mg/ml (4.1), healthy: 8.1mg/ml (8.6)).[37] Phosphatidylcholine, an essential constituent for 238 
the normal mucus barrier function, was strongly decreased in the colonic mucus barrier of 239 
patients with UC (-70%) [as measured by mass spectrometric analysis of lipid extracts of 240 
specimens of rectal mucus]. Beneficial effects were shown when phosphatidylcholine was used 241 
as a treatment option for UC.[47-49] Due to the low number of subjects only a trend to lower 242 
concentrations of phosphatidylcholine could be observed in the ascending colon fluids of UC 243 
patients in relapse (0.31mM) or remission (0.30mM) in the fasted state compared to controls 244 
(0.36mM).[37; 39] The faecal fluids of patients with UC were found to have a lower concentration 245 
of potassium (33.0mmol/l vs. 84mmol/l) and a higher concentration of sodium (67.8mmol/l vs. 246 
34mmol/l) and chloride (53.1mmol/l vs. 18.5mmol/l) compared to healthy subjects.[50] 247 
 248 
Regarding the properties of the ascending colon fluid of patients with UC, both the volume  249 
and surface tension were similar compared to controls (relapse: 26.8ml (13.5), remission: 250 
21.2ml (8.8), controls: 22.3ml (7.7) and relapse: 41.6mN/m (3.1), remission: 40.6mN/m (3.4), 251 
controls: 39.2mN/m).[37] The buffer capacity of the ascending colon fluid in remission and 252 
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relapse were similar but higher than in controls (with hydrochloric acid relapse: 253 
32.0mmol/l/ΔpH (18.1), remission: 37.7mmol/l/ΔpH (15.4), controls: 21.4mmol/l/ΔpH (7.9); 254 
with sodium hydroxide solution: relapse: 18.3mmol/l/ΔpH (10.4), remission: 16.7mmol/l/ΔpH 255 
(5.8), controls: 10.3mmol/l/ΔpH).[37] Osmolality values were higher in patients with UC in 256 
relapse (199.6±127.4mOsmol/kg) and remission (290.1±165.6mOsmol/kg) compared to 257 
controls (80.6±102.5mOsmol/kg).[37] Faecal fluid osmolality was similar to controls 258 
(341.1mOsm/kg vs. 348.5mOsm/kg).[50] 259 
2.1.3.2. Crohn’s disease 260 
The composition of GI fluids in patients with Crohn’s disease has not been described. The bile 261 
acid pool size (weight of total bile acids) was decreased to only 38-58% in patients with CD 262 
compared to controls as measured by induced gall bladder evacuation, subsequent aspiration 263 
of the duodenal fluid and analysis of labelled bile acid (previously administered) vs. total bile 264 
acid concentrations.[51-53] It has been reported that >90% of patients with resected CD and 11-265 
52% of patients with unresected CD suffer from bile acid malabsorption.[54] As a consequence, 266 
postprandial duodenal bile acid concentrations were decreased in 9 of 19 CD patients with a 267 
mean value of 6.04mM (3.92).[55] The failure in the reabsorption of bile acids is a result of the 268 
disease localisation in the ileum, as the ileac sodium/bile acid cotransporter is responsible for 269 
the active reabsorption of the conjugated bile acids. As a consequence, bile acid malabsorption 270 
is particularly severe in CD patients after resection of the distal ileum.[56]  271 
With regard to the properties of the GI fluids, faecal fluid osmolality in CD patients was 272 
increased (132-152%) as observed in two studies.[50; 57] 273 
Changes in the exocrine pancreatic function have also been reported in CD. A significant 274 
decrease of amylase (33-85%), trypsin (29%) and lipase (28-80%) activity in the fed state in 275 
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the duodenum of CD patients compared to controls was observed which was particularily 276 
strong in malnourished patients.[45; 58; 59] 277 
2.1.4. Permeation and transport systems 278 
Transporters in the GI tract can increase drug bioavailability by transferring drugs from the 279 
luminal to the basolateral site (uptake transporters) or decrease drug absorption by transport in 280 
opposite direction (efflux transporters).  281 
For uptake transporters, differences in the transporter expression have been reported in IBD. 282 
The expression of OCTN1 and OCTN2, transporters for cationic drugs, is downregulated in 283 
UC patients and IBD patients were found to have mutations in the genes encoding their 284 
expression.[60; 61] The expression of PepT1, an important influx transporter for 285 
peptidomimetics, is upregulated in the colon in chronic inflammation associated with IBD, 286 
with no information being available for its expression in the small intestine of these patients.[61] 287 
In healthy adults PepT1 is majorly expressed in the small intestine and only very low amounts 288 
of PepT1 are expressed in the colon.[61] Therefore, alterations in the colonic expression pattern 289 
of PepT1 may have only limited influence on drug absorption of peptidomimetics such as β-290 
lactam antibiotics and angiotensin-converting enzyme inhibitors. 291 
2.1.4.1. Ulcerative colitis 292 
The composition of the gastrointesinal membranes can be altered by GI diseases and thus, 293 
influence drug permeation. The thickness of the colonic and rectal mucus layer was reduced in 294 
UC patients compared to controls which was more pronounced in distal regions (right colon: 295 
90(79) vs. 107(48)µm, left colon: 43µm (45) vs. 134µm (68), rectum: 60µm (86) vs. 155µm 296 
(54)).[62] 297 
The efflux transporters, P-glycoprotein(P-gp), BCRP and MRP2 are the most important efflux 298 
transporters in the luminal membrane of the small intestine and they act by limiting cellular 299 
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uptake into the enterocyte and enhancing the excretion of xenobiotics.[63] The expression levels 300 
of BCRP, MRP2 and P-gp in the colonic and rectal mucosa of UC patients are strongly 301 
decreased during active inflammation.[64] In contrast, elevated levels of P-gp in the colon of 302 
UC patients were found in another study possibly due to a milder disease state in the study 303 
subjects.[64] The bioavailability of sulfasalazine, a substrate of MRP2 and BCRP and prescribed 304 
for IBD, could thus be increased in UC and produce more side effects.[61]  305 
2.1.4.2. Crohn’s disease 306 
The thickness of the colonic and rectal mucus layer was increased in CD patients compared to 307 
controls (right colon: 190(83) vs. 107(48)µm, left colon: 232(40) vs. 134(68)µm, rectum: 308 
294(45) vs. 155(54)µm).[62] 309 
Baseline permeability in surgical specimens from the distal ileum of CD patients was similar 310 
compared to colon cancer patients as measured by permeability to 51Cr-EDTA and electrical 311 
resistance in Ussing chambers.[66] However, after exposure to sodium caprate, a stimulus to the 312 
luminal epithelium, the increase in paracellular permeability in CD was more pronounced.[66] 313 
This hyper responsiveness might be of particular interest because certain drugs may act as 314 
luminal stimulus.  315 
Paracellular permeability for various compounds like 51Cr-EDTA, [99mTc]DTPA, sucrose 316 
and lactulose was increased in patients with CD compared to controls probably caused by the 317 
opening of tight junctions.[67-70]  318 
Transcellular permeability, as indicated by mannitol’s permeability in in vivo 319 
lactulose/mannitol intestinal permeability studies, was not altered in CD patients compared to 320 
controls.[71; 72] Mannitol is absorbed via the paracellular pathway in in vitro permeability studies 321 
(e.g. Ussing chambers), whereas in in vivo intestinal permeability studies it is used as marker 322 
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for the transcellular route due to a solvent drag effect caused by the hyperosmolality of villus 323 
tips.[73] 324 
Active transport systems can also be altered in CD. The expression of P-gp was increased to 325 
over 200% in the duodenal biopsy specimens and in the colon of CD patients.[65; 74] This 326 
increased P-gp expression could be responsible for the decreased absorption of tacrolimus and 327 
justify the higher doses of tacrolimus required in a patient with CD.[74] 328 
2.1.5. Metabolism 329 
2.1.5.1. Ulcerative colitis 330 
The expression of metabolizing enzymes in the large intestine of patients with UC is altered 331 
compared to controls. In colorectal tissue the expression of the most abundant metabolizing 332 
enzyme, CYP3A4, was slightly elevated (125%) but the expression of CYP2C9, CYP1A1 and 333 
UDP-glucuronic acid transferase was decreased in enterocytes (74%, 81%, 72%).[65] In biopsy 334 
samples of the terminal ileum and various regions of the colon the expression of CYP3A and 335 
CYP2D6 was not altered but the expression of CYP1A1 was increased.[75] Whereas in the 336 
terminal ileum and colon no difference in CYP2E1 expression compared to controls was 337 
observed, one study found increased expression (137%) in colorectal tissue probably due to the 338 
inflammation processes in active disease.[65; 75]  339 
Considering conjugation reactions, sulphation by sulfotransferases in the colonic mucosa of 340 
UC patients was reduced to <15% compared to controls.[76] The systemic sulphation pathway 341 
is not reduced as shown by no alteration in paracetamol metabolism in UC patients.[77] 342 
2.1.5.2. Crohn’s disease 343 
Patients with CD displayed different expression patterns for metabolizing enzymes. The 344 
expression of CYP3A4 was more than doubled in the colon of CD patients compared to 345 
controls and also increased, together with CYP3A5 expression, in duodenal biopsies of 346 
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children with CD.[65; 78] This may alter the bioavailability of substrates for both enzymes such 347 
as corticosteroids. In a recent study, lower CYP3A4 activity was shown in patients with CD as 348 
assessed after intravenous and oral administration of midazolam (CYP3A4 substrate).[79] This 349 
finding was mainly attributed to a lower hepatic CYP3A4 activity (hepatic extraction ratio in 350 
CD patients 0.11 vs. 0.36-0.62 in healthy subjects; intestinal extraction ratio in CD patients 351 
0.64 vs. 0.30-0.61 in healthy subjects). Furthermore, in the same study the 25% of the 352 
variability in budesonide pharmacokinetics (CYP3A4 substrate) was attributed to the reduced 353 
CYP3A4 activity.  354 
Elevated expression of other metabolizing enzymes like CYP2C9 (130%), CYP1A1 (134%) 355 
and UDP-glucuronic acid transferase (135%) was also observed.[65; 75] CYP2B6 levels were 356 
augmented to 178% in CD patients and the expression of glutathione-S-transferase was 357 
strongly raised (159-167%).[65] A tendency to increased levels of CYP2E1 (122%) was 358 
reported.[64; 74] CYP3A and CYP2D6 expression was similar to controls.[75]  359 
 360 
2.1.6. Microbiota 361 
In recent years, the importance of the GI microbiota in IBD patients is increasingly recognised. 362 
At the early stages of IBD differences in the microbiota (dysbiosis) are already present and the 363 
role in disease etiology and disease progression is currently being investigated.[80] The 364 
emergence of several new methodologies (metagenomic sequencing, transcriptomics and 365 
metabolomics) in the last years has provided information on bacterial functions over and above 366 
the broad taxonomic profiles.[80] The microbiota of patients with IBD was decreased in 367 
diversity, as the gene catalogue of the human gut microbiome in IBD patients showed 25% less 368 
bacterial genes compared to controls, with a shift to more potentially inflammatory and less 369 
potentially protective bacterial species.[80; 81] Reduced amounts of Faecalibacteria, 370 
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Leuconostocaceae, Odoribacter splanchnius, Phascolarctobacterium and Roseburia in IBD 371 
patients led to decreased levels of short chain fatty acids (SCFA) which are involved in immune 372 
regulatory functions and stimulate bile acid production and mucosal protection.[80; 82-84] Several 373 
drugs are processed by bacterial enzymatic action which is possibly affected by the altered 374 
composition of the microbiota observed in IBD (Table 4). 375 
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2.1.6.1. Ulcerative colitis 376 
The microbiota of UC patients was richer in Proteobacteria, Bacteroides, Fusobacteria and 377 
Enterobacteriaceae compared to controls.[89] Decreased levels of Faecalibacterium prausnitzii, 378 
Bacteroides fragillis, Ruminococcus albus, Roseburia intestinalis, Clostridium coccoides, 379 
Eubacterium rectale, enterohepatic Helicobacter species and the Clostridium leptum group 380 
were observed.[89] 381 
Small intestinal bacterial overgrowth (SIBO) was slightly more prevalent in UC patients 382 
compared to controls (17.8 % vs. 0.86%).[29] In terms of enyzmatic bacterial function, 383 
differences in the colonic mucus of patients with UC were observed. Proteinase activity 384 
(657.6units h-1mg dry wt.-1 (150.6) vs. 77.2units h-1mg dry wt.-1 (25.9)) and non-specific 385 
esterase activity (39.8µmol h-1 mg dry wt.-1 (3.3) vs. 33.9µmol h-1 mg dry wt.-1 (3.7)) were 386 
increased compared to controls.[90] 387 
2.1.6.2. Crohn’s disease 388 
Changes in bacteria species colonizing the intestine of CD patients were observed with higher 389 
amounts of Bacteroidetes and Enterobacteriaceae, specifically Eschericia coli, and lower 390 
amounts of Firmicutes and Faecalibacterium prausnitzii compared to healthy subjects.[91]  391 
45.2% of patients with CD suffered from SIBO compared to only 0.86% of controls.[29] With 392 
regard to bacterial enzyme activity, decreased faecal azoreductase activity (11.39mU/g vs. 393 
51.13mU/g), extremely high proteinase activity (585.8units h-1mg dry wt.-1 (202.1) vs. 394 
77.2units h-1mg dry wt.-1 (25.9)) and elevated non-specific esterase activity (51.7µmol h-1 mg 395 
dry wt.-1 (19.7) vs. 33.9µmol h-1 mg dry wt.-1 (3.7)) were observed in CD.[85; 90] 396 
2.2. Celiac disease 397 
2.2.1. General information 398 
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Celiac disease, affecting 1% of the population, is a genetic autoimmune enteropathy with a 399 
hypersensitivity of the patient to gluten.[92; 93] A small intestinal biopsy which shows villous 400 
atrophy, crypt hyperplasia and intraepithelial lymphocytosis serves as an additional diagnostic 401 
criteria.[93] Normally, the villous atrophy, occurs in patches and is localized at the duodenal 402 
bulb and in the descending duodenum but more distal GI segments can also be affected. The 403 
villous atrophy results in decreased availability of absorptive surface area leading to impaired 404 
drug and nutrient absorption.[94]  405 
2.2.2. Gastrointestinal transit time/motility and pH 406 
The mouth-to-cecum transit time in untreated patients with celiac disease was prolonged 407 
compared to controls using the lactulose breath test but significantly decreased after treatment 408 
with a gluten-free diet (Table 5).[95-97] Gastric emptying time measured with 13C-octanoic acid 409 
breath test and ultrasonographic emptying studies in untreated patients with celiac disease was 410 
increased but normalized after treatment with a gluten-free diet.[92; 98; 99] However, with another 411 
methodology (small bowel PillCam®) gastric emptying was found to be similar to controls.[98] 412 
No alteration of small intestinal transit time was found in celiac disease patients. The faster 413 
mean colonic transit time, as measured in one study (n=40) only, was attributed to a 414 
subpopulation of patients with very fast colonic transit.[97]  415 
Motility changes in celiac disease patients compared to controls were observed with increased 416 
oesophageal motility disturbances.[101] 417 
With regard to the pH profile in patients with celiac disease, a higher jejunal surface pH value 418 
with a pH of 6.42 (0.06) or 6.56 (0.14) in untreated patients, 6.32 (0.07) or 6.19 (0.09) in treated 419 
patients compared to 5.96 (0.05) or 5.93 (0.05) in controls was observed which might favour 420 
the absorption of weakly basic drugs.[102; 103] Intraluminal pH measurements confirmed a higher 421 
pH in the proximal small bowel and showed similar pH values in the stomach.[104] 422 
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2.2.3. Composition of luminal contents 423 
The composition of GI fluids in patients with celiac disease has not been described. About 20% 424 
of patients with untreated celiac disease showed a decreased secretion of at least one pancreatic 425 
enzyme.[105] Reduced cholecystokinin secretion as response to a meal, which was observed in 426 
celiac disease patients, could lead to decreased gall-bladder motility and small intestinal transit 427 
time.[106] This could further provoke an increase and stasis of the bile acid pool.[106; 107] 428 
Additionally, increased biliary outputs of phospholipids (0.26mg/kg*h (0.05) vs. 0.08mg/kg*h 429 
(0.02)), cholesterol (0.82mg/kg*h (0.10) vs. 0.43mg/kg*h (0.06)) and bile acids (9.28mg/kg*h 430 
(1.65) vs. 4.64mg/kg*h (0.45)) were all observed in celiac disease patients.[108] 431 
Protein concentrations in jejunal perfusion fluids were altered in celiac disease patients 432 
compared to controls. The concentration of glycosaminoglycan hyaluronan, a connective 433 
membrane component, was increased two-fold in the basal state of celiac disease compared to 434 
controls.[109] After provoking an immune response by challenging the jejunal segment with 435 
gliadin (protein present in wheat), concentrations of albumin and glycosaminoglycan 436 
hyaluronan increased up to two-fold indicating increased protein leakage through the GI 437 
membrane.[109]  438 
2.2.4. Permeation and transport systems 439 
Differences in paracellular passive diffusion were observed in patients with celiac disease 440 
compared to controls with a higher GI permeability of lactulose and 51Cr-EDTA, possibly due 441 
to opening of the tight junctions.[71; 110-113]  442 
For the transcellular pathway, a lower permeability for mannitol and polyethylene glycol 400 443 
was observed in in vivo intestinal permeability studies, possibly due to the decrease in the 444 
absorptive surface area.[110-113] 445 
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In the case of efflux transporters, the expression of P-gp in untreated and treated children with 446 
celiac disease was elevated compared to controls whereupon gluten withdrawal resulted in a 447 
further increase.[114] 448 
2.2.5. Metabolism 449 
Jejunal morphological changes like flattened villi in celiac disease were accompanied by 450 
different activity of metabolic enzymes. The CYP3A activity was decreased in patients with 451 
celiac disease but treatment with a gluten-free diet subsequently resulted in increased 452 
activity.[115] Accordingly, the expression and activity of CYP3A4 in children with celiac 453 
disease was reduced.[116] 454 
2.2.6. Microbiota 455 
The microbiota of celiac disease patients was found to be rich in potentially pathogenic gram-456 
negative bacteria and poor in species such as Lactobacilli and Bifidobacteria compared to 457 
controls.[117] After treatment with a gluten-free diet the microbiota shifted to more beneficial 458 
species.[117] The prevalence of SIBO in celiac disease patients is not evident due to the 459 
heterogeneity of studies (differences in inclusion criteria, no homogeneous controls groups, 460 
low study quality), whereas SIBO prevalence appears to be higher in patients with celiac 461 
disease patients with persisting symptoms following withdrawal of gluten.[118-121] 462 
2.3. Irritable bowel syndrome 463 
2.3.1. General information 464 
Irritable bowel syndrome (IBS) is a chronic GI disorder, prevalent in 5-11% of the population 465 
in most countries, with symptoms such as recurring abdominal pain, bloating and changes in 466 
the pattern of bowel movements.[122] The disease can either be predominated by diarrhoea (IBS-467 
D) or constipation (IBS-C) or it can be a combination of both (IBS-M). The recrudescence of 468 
the symptoms is often linked with psychological stress.  469 
22 
 
2.3.2. Gastrointestinal transit time/motility and pH 470 
Gastric emptying time and small intestinal transit time were not significantly different in IBS 471 
patients compared to controls measured with a SmartPill GI monitoring system (51.23min 472 
(59.1) vs. 76.81min (73.2) and 218.56min (59.60) vs. 199.20min (82.31)).[123] Differentiation 473 
between IBS subtypes, revealed that small bowel transit time and total GI transit time were 474 
shorter in IBS-D patients (3.3h (0.3) vs. 4.2h (0.2) and 35h (5) vs. 53h (4)) and prolonged in 475 
IBS-C patients (5.4h (0.3) vs. 4.2h (0.2) and 87h (13) vs. 53h (4)).[124]  476 
The pH profile in IBS patients in the fasted state was similar to controls throughout the four 477 
quartiles of the small intestine indicating no alteration in the ionization of administered drugs 478 
compared to controls.[123]  479 
2.3.3. Composition of luminal contents 480 
The composition of GI fluids in patients with IBS has not been described. Around 32% of IBS 481 
patients suffer from moderate bile acid malabsorption with a 10% prevalence of severe bile 482 
acid malabsorption.[125] Patients with IBS-D, showing a decreased bile acid deconjugation 483 
activity in the faeces, have increased levels of faecal primary bile acids, chenodeoxycholic 484 
acid, sulphated bile acids and ursodeoxycholic acid and decreased levels of faecal secondary 485 
bile acids.[126] Bile acid deconjugation activity was also decreased in the faeces of IBS-C 486 
patients.[126]  487 
2.3.4. Permeation 488 
Not all patients with IBS showed an increase in intestinal permeability but for the subgroup of 489 
IBS-D patients a higher intestinal permeability was observed more frequently.[127] Rectal 490 
permeability tests in patients with IBS-D observed that the passage of macromolecular 491 
compounds through rectal biopsies was increased.[128] 492 
23 
 
2.3.5. Microbiota 493 
The GI microbiota of patients with IBS has been analysed in several studies but inconsistent 494 
results have been published due to the lack of differentiation between disease subtypes, the 495 
pathophysiology of the disease and the methods used. Patients with IBS had a higher amount 496 
of mucosa-associated bacteria at the rectal epithelium than healthy controls.[129] The faecal 497 
microbiota was reduced in the Clostridium coccoides subgroup and the Bifidobacterium 498 
catenulatum group and a high ratio of Firmicutes to Bacteroidetes was found in a subgroup of 499 
IBS patients.[130-132] The IBS-D subtype could be distinguished by decreased levels of 500 
Lactobacillus spp., Bifidobacteria and increased levels of Escherichia coli.[126; 129; 132] The 501 
microbiota of IBS-C patients was richer in Bacteroides, Veillonella spp. and 502 
Bifidobacterium.[126; 132]  503 
2.4. Short Bowel Syndrome 504 
2.4.1. General information 505 
Short bowel syndrome (SBS) is a malabsorption disorder as a result of the loss of a large part 506 
of the bowel due to surgical resection, congenital defects or disease resulting in a remaining 507 
intestinal length of less than 200 cm.[133; 134] The diminished intestinal surface area impedes 508 
absorption and thus, causes the dehydration and malnutrition with micronutrients and 509 
macronutrients of SBS patients which cannot always be overcome with enteral 510 
supplements.[135; 136] Drug absorption can equally be impaired in SBS patients and for poorly 511 
absorbed drugs alternative routes of administration should be considered.[137] 512 
2.4.2. Gastrointestinal transit time/motility and pH 513 
GI transit time in patients with severe SBS was largely decreased impeding nutrient absorption 514 
as well as drug absorption.[138] Different GI transit times according to the method used were 515 
observed in patients with SBS: 52.5 minutes (lactulose hydrogen breath testing), 967 minutes 516 
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(radiopaque markers) and 96.3 minutes (blue food colour to appear in ostomy effluent or stool). 517 
Limitations of the methods include that lactulose hydrogen breath testing can only be used in 518 
patients with intact ileocecal valve and the much longer transit time with a radiopaque marker 519 
indicates that anatomical changes prevent the passage of the marker.[138] Therefore, stagnation 520 
of solid oral dosage forms in the GI tract of SBS patients might also occur and result in a 521 
different exposure to the absorptive surfaces and increased variability of drug absorption.  522 
The pH profile in the stomach of patients with SBS was similar compared to controls but higher 523 
pH values in the small intestine (6.03 vs. 5.39) and right colon (6.7 vs. 5.8) were observed 524 
(Figure 3).[44; 139-141]  525 
2.4.3. Composition of luminal contents 526 
Gastric acid hypersecretion, which can be five-fold greater than basal levels in healthy subjects, 527 
is often experienced during the acute stage after surgical resection by patients with SBS. [142] 528 
This can result in a pH reduction causing the inactivation of GI fluid components such as 529 
pancreatic enzymes. Due to adaptation processes the hypersecretion is normalised during the 530 
first weeks or month after resection.[143]  531 
Bile acid malabsorption as a result of the removal of parts of the ileum, their main reabsorption 532 
area, results in decreased recirculation of bile salts and a spill over of bile salts to the colon.[142] 533 
To compensate for the bile acid loss bile salt production is increased in SBS patients, reaching 534 
10 to 20 fold the production of healthy individuals.[144] If the increased production cannot fully 535 
compensate the loss, lower amounts of bile acids in the intestine can prevent the solubilisation 536 
and absorption of fatty acids as well as of lipophilic drugs.[145] Choleretic diarrhoea, caused by 537 
increased levels of bile salts in the colon and the subsequent loss of chloride and water, could 538 
also affect colonic transit time.[142] 539 
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2.4.4. Permeation 540 
After removal of a large part of the intestine the remnant parts of the bowel undergo a natural 541 
adaption process including changes in the expression of membrane transporters in order to 542 
improve the absorption of nutrients.[146] Patients with SBS had an increased amount of PepT1 543 
mRNA in the colon 1.5–2.5 years after resection with normalization over time (9.8 ± 5.7 years 544 
after resection).[147; 148] 545 
2.4.5. Microbiota 546 
The faecal and mucosa-associated microbiota of patients with SBS was deeply altered 547 
compared to controls. It was rich in Lactobacillus, resulting in a greater absorption of 548 
carbohydrates in SBS patients, and the specific species Lactobacillus mucosae was prevalent 549 
in most samples of SBS patients while it was not detected in controls. [147] Decreased amounts 550 
of Clostridium leptum, Clostridium coccoides, Bacteroidetes, Firmicutes, Bifidobacterium and 551 
Methanobrevibacter smithii were found in patients with SBS.[134; 149] 552 
Higher risk of SIBO in patients with SBS is a result of the stagnation of intestinal contents, the 553 
impairment of the ileocecal valve and the reduction of the terminal ileum which favours 554 
bacterial growth in higher parts of the GI tract.[142] As a consequence, deficiencies of fat-soluble 555 
vitamins, problems in fat absorption and increased intestinal permeability can occur.[142] 556 
In summary, an overview of the changes affecting drug absorption in GI disease patients 557 
compared to controls is given in Figure 4.558 
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3. Drug-related factors affecting absorption in GI diseases 559 
3.1. Molecular weight 560 
The molecular weight (MW) in conjunction with other physicochemical characteristics such as 561 
the charge of the molecule, its hydrophilicity and shape determines the pathway and extent of 562 
drug permeability.[150] The rate of diffusion of a drug is inversely proportional to its molecular 563 
weight with high molecular weight compounds having low permeability. [150] Molecules with 564 
MW<200g/mol can permeate through tight junctions between intestinal cells via paracellular 565 
passive diffusion.[151]  566 
In CD and celiac disease, ruptures of the tight junctions can increase the permeability of larger 567 
drugs (MW>200g/mol) via the paracellular route by impairing the sieve effect of the tight 568 
junctions (Section 2.1.2.3 and 2.2.3). In celiac disease, the decreased absorptive surface area 569 
hinders the absorption of small drugs (MW<200g/mol) via the transcellular pathway, probably 570 
resulting in a decreased bioavailability compared to controls as indicated by the decreased 571 
permeability of mannitol (Section 2.2.3).  572 
Passive transcellular diffusion is restricted for drugs with MW>500g/mol whereas lipophilic 573 
drugs with MW 350±150g/mol can readily permeate through the intestinal membrane. In celiac 574 
disease, no correlation between drug absorption of different antibiotics and their molecular 575 
weight was observed since sulphamethoxazole (MW 253g/mol) and erythromycin stearate 576 
(MW 1018.4g/mol) showed a similar absorption pattern.[152] A possible explanation for this 577 
may be that the drugs use different pathways to pass the epithelial membrane.   578 
The bioavailability of methyldopa (MW 211g/mol, BCS class III compound) was significantly 579 
increased in celiac disease patients (n=10, Cmax 5.0µg/ml (2.2) vs. 3.1µg/ml (1.1), AUC 20.5µg 580 
ml-1h (9.6) vs. 13.4µg ml-1h (4.9)), without a change in the pharmacological response.[153; 154] 581 
It should be noted that the patients were already on treatment (gluten-free diet) and more 582 
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pronounced differences could be expected in patients without treatment. Since levodopa is 583 
completely absorbed via efficient transepithelial carrier transport and the recovery of 584 
methyldopa in urine and feces was not altered in celiac disease patients, increased paracellular 585 
permeability might not be relevant and the finding might be attributed to other factors such as 586 
decreased renal excretion.[155] In contrast, CD patients (n=5) had lower plasma levels of 587 
methyldopa (AUC 8.7µg ml-1h (4.3) vs. 13.4µg ml-1h (4.9)) and a reduction in the 588 
pharmacological response (sedation, smaller decrease in systolic blood pressure).[154] 589 
Acetaminophen (BCS class I compound) with a low MW of 151g/mol is partly absorbed via 590 
the paracellular pathway.[153; 156] Acetaminophen absorption in patients with celiac disease and 591 
CD was delayed (celiac untreated AUC0-1h 9.0μg min/ml (1.6), celiac treated AUC0-1h 8.2μg 592 
min/ml (2.0), CD 9.3μg min/ml (3.5) vs. controls AUC0-1h 12.4μg min/ml (3.2)) probably due 593 
to delayed gastric emptying but the overall acetaminophen absorption was not impaired as 594 
indicated by urinary recovery.[157] In SBS patients, total absorption of acetaminophen was 595 
decreased as the drug is absorbed in the jejunum and thus, rectal drug administration should be 596 
preferred.[158] It should be noted that the changes in the jejunal morphology due to celiac disease 597 
did not impair the overall absorption of acetaminophen.[157] 598 
Tioguanine (MW 167g/mol, log P -0.07) showed highly variable absorption in CD patients 599 
possibly due to altered paracellular passive diffusion, with possible implication in treatment. 600 
[159] Differences in AUC were 4 to 7-fold and in two patients no tioguanine absorption was 601 
observed within 6 hours after oral intake for at least one of three different formulations 602 
investigated.[160] 603 
3.2. Lipophilicity 604 
Lipophilicity has a high influence on the bioavailability of a drug by affecting its solubility, 605 
permeability and metabolism.[161] Drugs can be classified according to their logP in highly (log 606 
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P>3), moderately (log P 1-3) and low (log P<1) lipophilic drugs.[162] For highly lipophilic drugs 607 
(log P>3) the dissolution and solubility in the aqueous GI fluids is often the rate limiting factor 608 
for drug absorption since only the dissolved part of a drug can permeate through the GI 609 
membranes and thus, reach the systemic circulation. Alterations in GI diseases can provoke 610 
changes in the bioavailability of lipophilic drugs due to changes in GI transit times, reduced GI 611 
volumes leading to non-sink conditions and increased surface tension hindering the wetting of 612 
the drug surface. Micellar drug solubilisation can also be affected by decreased concentrations 613 
of amphiphilic bile components and a reduction in absorptive surface area limits the permeation 614 
of drugs via transcellular passive diffusion.  615 
In CD, decreased amounts of bile acids in the luminal fluids, reduced absorptive surface area 616 
depending on the location of the disease, and increased small intestinal transit time can affect 617 
the absorption of lipophilic drugs (Section 2.1). In celiac disease, impacting factors are the 618 
increased concentrations of bile salts and lecithin, increased orocecal transit time and the highly 619 
decreased absorptive surface area (Section 2.2). 620 
In CD patients, a highly lipophilic drug, propranolol (log P 3.48, pKa 9.42), showed a higher 621 
bioavailability and increased plasma levels possibly due to prolonged small intestinal transit 622 
time. Since propranolol is a highly soluble compound (BCS class I), decreased bile salt 623 
concentrations are expected to be only secondary.[163; 164] Further investigations with multiple 624 
dosing are needed in order to assess if the increased bioavailability is clinically relevant. It 625 
should be noted that conflicting results regarding propranolol absorption in celiac disease 626 
patients have been reported with in some cases higher propranolol absorption in celiac disease 627 
compared to controls whereas in other cases similar absorption was found.[4; 102; 163; 165; 166] 628 
Higher propranolol absorption correlated in one study with a measured higher jejunal surface 629 
pH resulting in a higher unionized fraction of propranolol but could also be the result of higher 630 
bile salt and phospholipid concentrations or the atropic mucosa favouring the transport of 631 
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lipophilic drugs. However, jejunal perfusion showed lower propranolol absorption in the 632 
jejunum which was apparently compensated in lower intestinal parts.[166]  633 
For levothyroxine, another highly lipophilic drug (log P 3.51) with a narrow therapeutic index, 634 
celiac disease patients needed higher initial doses to maintain a euthyroid state (154µg (65) vs. 635 
106µg (46)), which decreased (111µg) after gluten withdrawal.[167; 168] This could be attributed 636 
to the reduced absorptive surface area in the small intestine in celiac disease patients (Section 637 
2.2).  638 
In CD and UC, the absorption of prednisolone (log P 1.62, BCS class I), a moderately lipophilic 639 
drug, was delayed possibly due to the increased gastric emptying time.[153; 159;169] In one study 640 
overall prednisolone absorption in CD patients was only impaired in patients with extensive 641 
disease manifestation in the small bowel, whereas in another study a decreased bioavailability 642 
of 0.6 (0.2) compared to 0.86 (0.09) in controls was observed also for CD patients with a 643 
different disease localisation.[169; 170] The authors of the first study postulated that the 644 
methodology of the latter study might have been more sensitive as it included measurements 645 
of serum, urine and stool recovery of prednisolone. Highly variable prednisolone serum levels 646 
in CD patients with higher disease activity could be attributed to altered CYP3A4 activity.[171] 647 
Surprisingly, prednisolone absorption was not altered in patients with celiac disease where 648 
absorptive surface area is reduced due to the villous atrophy.[171; 172] 649 
For drugs with low lipophilicity and high hydrophilicity following paracellular permeability, 650 
molecular weight (Section 3.1) and charge (Section 3.3) need to be considered for the 651 
evaluation of absorption of these drugs in GI diseases.  652 
3.3. Degree of ionization 653 
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The degree of ionization influences both the solubility and the permeability of drugs and 654 
subsequently the rate of drug absorption. The degree of ionization is dependent on the drug 655 
itself and the pH value of the enclosed GI fluids.  656 
Weak bases are protonated and therefore, more soluble in the more acidic compartments of the 657 
GI tract (stomach, proximal small intestine). Subsequent increase in pH, when the drug enters 658 
the duodenum, may result in a supersaturated state and enhance drug absorption.[169] The 659 
unionized form of a drug permeates more readily through the GI membrane and therefore, drug 660 
absorption of weak bases is higher in GI compartments with higher pH. In CD, the pH of the 661 
stomach is elevated (Section 2.1.2) and decreased solubilisation of weak bases would be 662 
expected.  663 
Weak acids are more soluble in GI compartments with a higher pH due to their ionisation 664 
profile, but membrane permeation for the more ionized fraction of the drug is impeded.[174] In 665 
celiac disease and SBS, small intestinal pH was higher compared to controls which could 666 
possibly increase absorption of weak bases (Section 2).  667 
The absorption of a weak acid, folic acid (pKa 4.7), was decreased in celiac disease patients 668 
possibly due to the lower absorptive surface area and the slightly elevated jejunal pH (Section 669 
2.2) and therefore, higher ionized amount of folic acid.[102; 175] Folate is highly absorbed in the 670 
more acidic milieu in the duodenum and proximal jejunum since the removal of these parts 671 
results in folate deficiency that is commonly observed in celiac disease patients.[176]  672 
For two other weak acids, indomethacin (BCS class II) and acetylsalicylic acid (BCS class I), 673 
no effect on overall absorption was observed in patient with celiac disease. Only a faster 674 
absorption rate (Celiac disease: tmax 0.80h (0.60), controls: tmax 1.09h (0.16)) was found for 675 
acetylsalicylic acid probably due to faster gastric emptying in the fasted state (Section 2.3.1) 676 
or differences in drug permeability.[153; 177] Thus, the slightly higher jejunal pH that might 677 
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decrease the unionized fraction of the drug available for absorption has no effect on absorption 678 
(Section 2.2.1). With acetylsalicylic acid, therapeutic outcomes were achieved in patients with 679 
SBS revealing no impairment of drug absorption.[178]  680 
4. Formulation-related factors affecting absorption in GI diseases 681 
Pharmaceutical formulations are designed to overcome the challenges of the GI tract and to 682 
deliver the active pharmaceutical ingredient into the systemic circulation. A variety of different 683 
approaches is used to optimize the bioavailability, safety and efficacy of the drug. Enteric-684 
coated formulations protect the drug from gastric acid or the stomach from the toxicity of the 685 
drug. Modified-release formulations can ensure constant drug levels, facilitate drug therapy by 686 
minimizing the administration frequency and deliver the drug locally to specific compartments 687 
of the GI tract. Immediate-release formulations are a simple approach if no further modification 688 
of the drug bioavailability is needed. In order to fulfil their purpose, the different formulations 689 
are designed based on the conditions of the GI tract in healthy subjects e.g., pH, microbiota 690 
and transit time (Section 2). However, these parameters can be altered in patients with GI 691 
diseases impacting the drug release/dissolution from the formulation.  692 
4.1. Immediate-release formulation 693 
For immediate release formulations, the disintegration of the pharmaceutical formulation, the 694 
disaggregation of the granules and finally the dissolution of the particles will be affected by 695 
the hydrodynamics in the GI tract. Transit times in the different GI compartments, altered by 696 
GI diseases (Section 2), affect the time until the absorption site is reached and the time available 697 
for absorption. Delayed gastric emptying as observed in CD and untreated celiac disease in the 698 
fed state (Section 2) can result in a delayed tmax since for most drugs the main absorptive area 699 
is the large surface area of the small intestine. Patients with faster gastric emptying may also 700 
show a shorter tmax.
[4] Differences in terms of bile salts as observed in celiac disease, CD and 701 
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SBS (Section 2) can affect the wetting of the pharmaceutical formulation and therefore, change 702 
the disintegration time. 703 
4.2. Modified-release formulation 704 
4.2.1. Time-controlled release 705 
For the treatment of IBD pharmaceutical formulations with time-controlled release mechanism 706 
have been developed to deliver drugs to their target site in the colon. Depending on the transit 707 
times in the different compartments of the GI tract the amount of drug available in each 708 
compartment may vary for these formulations. For UC a high variability in colonic transit time 709 
was observed while in CD passage through the colon was accelerated (Section 2.1.2.1 and 710 
2.1.2.2). Faster colonic transit time can lead to a large amount of drug not being released and 711 
therefore, failure of the therapeutic effect may occur. 712 
When a micro pellet formulation of mesalazine coated with ethyl cellulose (Pentasa®,Ferring 713 
Pharmaceuticals, Copenhagen, Denmark) was administered to healthy subjects, drug product 714 
performance was not affected by a laxative induced diarrhoea.[179; 180] Thus, reduced colonic 715 
transit time as observed in CD (Section 2.1.2.2) is not expected to affect drug release from this 716 
formulation.  717 
Administration of the multi-matrix formulation of mesalazine (Mezavant®, Lialda®, United 718 
States) in patients with UC could be affected by longer small intestinal and colonic transit 719 
times, as following the dissolution of the gastro-resistant coating drug release occurs after 720 
diffusion from the lipophilic and hydrophilic matrix (Section 2). Drug release might occur in 721 
more proximal GI compartments differing from controls in which disintegration of the 722 
formulation was observed between 4.8h and 17.4h after administration.[179]  723 
Administration of a controlled release pellet formulation of budesonide (Entocort®, 724 
AstraZeneca UK Limited, UK) showed increased systemic bioavailability in CD patients 725 
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compared to controls (20.5 % (15.1, 27.8) vs. 11.5 % (8.8, 15.0), AUC0-∞ 114.0 nmol*h ⁄ L 726 
(81.4, 159.5) vs. 60.4 nmol*h ⁄ L (45.1, 80.8)).[40] This effect could be attributed to the delayed 727 
gastric emptying observed and other factors such as the composition of GI fluids, differences 728 
in permeability and the colonic bacterial and intestinal metabolism. Differences in the 729 
pharmacokinetics of budesonide in CD patients could possibly result in treatment failure or 730 
increased side effects. 731 
4.2.2. pH-controlled release  732 
The alteration of the typical pH profile in GI compartments changes the release profile of 733 
pharmaceutical formulations with pH sensitive coatings. For enteric coated formulations the 734 
reduction of acid in the stomach in CD can lead to premature drug release in the stomach 735 
(Section 2.1.2.2). Increased gastric residence time as observed in celiac disease, UC and CD 736 
could delay drug absorption of enteric coated formulations (Section 2). 737 
Different mesalazine formulations with pH-controlled release behaviour are available for the 738 
therapy of IBD. Formulations with a coating of Eudragit-L (Salofalk®, Dr Falk GmbH, 739 
Freiburg, Germany), dissolving at pH ≥ 6, target the mid-ileum and colon, whereas a tablet 740 
coated with  Eudragit S (Asacol®,Tillotts Pharma AG, Ziefen, Switzerland), dissolving at pH 741 
≥ 7, targets the terminal ileum and colon.[179] Based on the lower colonic pH values in UC 742 
(Section 2.1.2.1), impairment of drug release from these formulations may take place where 743 
failure to reach the pH needed for dissolution of the polymer coating occurs.  744 
4.3. Azo-bonded prodrug formulations 745 
Colonic drug delivery, often used in IBD, can be achieved by administering prodrugs or 746 
polymer coatings, which are cleaved by colonic bacterial enzymes such as azoreductase leading 747 
subsequently to the release of the active metabolite/drug.  748 
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In GI diseases, three different aspects can affect drug release of azo-bonded prodrugs such as 749 
sulfasalazine and olsalazine. Firstly, a decreased intestinal transit time has been associated with 750 
less exposure of the prodrugs to bacterial action and enhanced faecal loss of the prodrugs.[180] 751 
The therapeutic efficacy could be affected in some IBD patients as colonic transit time was 752 
highly variable (Section 2.1.2). Secondly, reduced activity of bacterial azoreductase as 753 
observed in CD (Section 2.1.6.2) could lead to reduced prodrug activation. Thirdly, small 754 
intestinal bacterial overgrowth as observed in CD and UC (Section 2.1.6) could provoke 755 
prodrug activation in upper parts of the GI tract.  756 
5. Methods to predict drug product performance 757 
Throughout the different stages in pharmaceutical drug development, in vitro biorelevant 758 
release/dissolution models linked with physiologically based pharmacokinetic (PBPK) models 759 
are used to predict drug product performance.[12; 181] Media, that simulate closely the conditions 760 
in the GI tract of healthy subjects by incorporating e.g., phospholipids, bile salts and lipids, are 761 
termed biorelevant. By using biorelevant media and applying hydrodynamics to reflect the 762 
conditions in healthy subjects, successful predictions of the drug product performance can be 763 
established with in vitro dissolution/release testing.[182; 183] Nowadays, in vitro 764 
dissolution/release profiles are often further linked with PBPK models resulting in better in 765 
vivo predictions of drug bioavailability.[184-186] It should be noted that the design of in vitro 766 
dissolution/release and PBPK models is based on conditions in healthy subjects. A remaining 767 
challenge is the prediction of drug product performance in patients with GI diseases where 768 
absorption is expected to be impaired (Section 2). Therefore, the development of biorelevant 769 
in vitro dissolution/release tests in patients with GI diseases linked with PBPK models would 770 
be desirable. In the following sections, the need to develop both in vitro dissolution/release 771 
tests and PBPK models reflecting conditions found in GI disease which can be confidently used 772 
to predict drug product performance is discussed. 773 
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5.1. In vitro dissolution and release testing 774 
In vitro dissolution testing has been established in the pharmaceutical industry for quality 775 
control purposes for stability testing and to assure batch to batch consistency. For drug 776 
development, biorelevant in vitro dissolution and release testing is used for the development 777 
of pharmaceutical formulations, to predict the in vivo performance of a drug product and to 778 
develop in vitro/in vivo correlations (IVIVC) with the intention to reduce time-consuming and 779 
cost-intensive animal or human studies. In the development of a suitable biorelevant in vitro 780 
dissolution testing method, the physicochemical characteristics of the drug and the 781 
physiological conditions in the GI tract should be considered. Current in vitro dissolution tests 782 
incorporate hydrodynamic conditions and media based on the physiological conditions in 783 
healthy subjects.  784 
There is a need for biorelevant dissolution methodology to simulate the GI conditions in 785 
patients with GI diseases since pathophysiological changes (Section 2) are expected to have an 786 
impact on drug solubilisation and dissolution and subsequently on drug absorption. Currently, 787 
no in vitro dissolution and release tests reflect changes observed in patients with GI diseases.  788 
In vitro dissolution and release tests used for drugs in GI diseases, especially IBD, have been 789 
developed reflecting mainly the GI pH profile in healthy subjects. To study the release and 790 
dissolution of different colon-targeting mesalazine and budesonide formulations several in 791 
vitro dissolution methods have been developed (Figure 5).[187-190] In terms of media, GI fluids 792 
were simulated using simple pharmacopeia buffers (SGF, SIF, SCoF), biorelevant media 793 
(Fasted state simulated intestinal fluid) or media enriched with enzymes. Different buffer 794 
systems were used (phosphate and bicarbonate) whereas bicarbonate buffers were superior in 795 
predicting the in vivo performance of mesalazine formulations.[191] The passage through the 796 
different GI compartments is simulated by media changes, modifications of the pH value at 797 
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various time points and the total duration of the experiment (360-1440min). The models vary 798 
in the applied hydrodynamics due to differences in volumes of the media (200ml-1000ml), in 799 
the agitation rate (50-100rpm, 10dips/min) and in the choice of the dissolution apparatus (USP 800 
II or III dissolution apparatus).  801 
Bacterial enzymatic action, needed for colon-targeting drug delivery, was included in in vitro 802 
dissolution tests with USP dissolution apparatus in several ways spanning the simple addition 803 
of enzymes to the addition of rat caecal contents and human faecal slurries.[192] Drug 804 
metabolism by intestinal microbiota can further be tested in more complex in vitro GI 805 
simulators such as semi-continuous culture systems and continuous culture systems (e.g. TNO 806 
TIM-2 in vitro model of the colon) with anaerobic conditions in which pH, temperature and 807 
redox potential can be controlled.[11; 193; 194] 808 
For the development of biorelevant in vitro dissolution and release tests for patients with GI 809 
diseases, pathophysiological changes in terms of media, hydrodynamics and microbiota must 810 
be reflected in the experimental design.811 
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5.2. PBPK models 812 
Physiologically based pharmacokinetic (PBPK) models use preclinical in vitro data, 813 
physicochemical drug properties and physiological parameters to predict in vivo plasma 814 
concentration-time profiles.[12] PBPK modelling was first introduced to assess the toxicology 815 
of drugs and was in recent years established as useful biopharmaceutical tool to predict drug 816 
bioavailability. The mathematical modelling framework used incorporates the different 817 
compartments of the GI tract and evaluates absorption, distribution, metabolism and 818 
elimination of the studied compound.  819 
For patients with GI diseases PBPK models present a special opportunity to improve their drug 820 
therapy. Pathophysiological changes can affect drug absorption (Section 2) but only a minor 821 
part of drugs and pharmaceutical formulations is tested in a GI disease population. Especially 822 
for the medication of concomitant conditions, e.g. oncological or cardiovascular drugs, the 823 
impact of the GI disease on drug product performance is unknown. As human studies are very 824 
cost-intensive, this might not change in the coming years considering the heterogeneous and 825 
therefore small patient population in the different types of GI disease. Establishing predictive 826 
in silico models for the different GI disease states can help to implement appropriate dosing 827 
regimen and improve drug therapy management. 828 
For GI diseases, PBPK models should include all the pathophysiological changes relevant for 829 
drug absorption in patients with GI diseases compared to healthy subjects (Section 2). 830 
However, due to only a limited number of studies with small patient populations and a high 831 
inter- and intra-study variability the characterisation of the pathophysiological changes is 832 
challenging. Up to now, no PBPK models for patients with GI diseases have been developed 833 
but recently a PBPK model for patients after bariatric surgery (post sleeve gastrectomy, post 834 
Roux-en-Y gastric bypass, post biliopancreatic diversion with duodenal switch, post jejunoileal 835 
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bypass) was developed.[195] The virtual model showed that the bioavailability of 5 drugs 836 
(omeprazole, diclofenac, fluconazole, ciprofloxacin, simvastatin) in patients after bariatric 837 
surgery was highly dependent on drug-specific parameters. The model, based on the template 838 
for morbidly obese in the Simcyp Simulator v10 (Simcyp Limited, Sheffield, UK), integrated 839 
changes in gastric volume and emptying rate, GI pH, differences in small intestinal dimensions 840 
and motility, transit time, bile properties, renal function and serum protein levels as observed 841 
in literature. Predictions of oral bioavailability of atorvastatin and cyclosporine in patients post 842 
Roux-en-Y gastric bypass were confirmed by clinical data, however the absorption of 843 
atorvastatin was not captured in the model for patients with post biliopancreatic diversion with 844 
duodenal switch.[196] 845 
6. Conclusion and outlook 846 
Further elucidation of drug absorption profiles in patients with GI diseases could be highly 847 
beneficial. The significance of current studies is often limited by small patient populations, 848 
conflicting data and the difficulty to assess changes in different disease states. More in vivo 849 
data is needed to further assess the GI physiological conditions in patients with GI diseases. 850 
Oral absorption already shows a high interindividual variability in healthy adults. Different 851 
disease states and disease localization make it even more difficult to assess absorption profiles 852 
in this heterogeneous group. In order to improve drug therapy for patients with GI diseases 853 
their medication should be tested under conditions specific to the particular pathophysiology. 854 
The ability to predict the in vivo performance of drug products in patients with GI diseases will 855 
be contingent on the development of appropriate biorelevant dissolution testing linked with 856 
PBPK models simulating pathophysiological conditions. Medication for concomitant diseases 857 
is seldom tested in GI disease patients. For these drugs the development of more cost-effective 858 
and less time-consuming alternatives to expensive clinical trials would represent an opportunity 859 
to improve drug therapy. Predicting the probability that a drug will be affected by certain GI 860 
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diseases depending on its physicochemical properties, would further limit the amount of 861 
experimental and computational work required. 862 
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Table 1: Gastrointestinal transit times in Ulcerative Colitis. Mean/Median (SD), rUC= UC patients in remission, aUC= active UC, dUC=distal UC, daUC=distal active UC, 1285 
sUC=severe UC, drUC= distal UC in remission 1286 
Total 
gastrointestinal 
transit 
Gastric emptying 
time 
Small intestinal 
transit time  
Colorectal 
transit time  
Proximal 
colon 
Middle and 
distal colon 
Orocecal transit 
time 
Meal Number of study subjects Method Reference 
sUC: 44.5h  
rUC: 51.8h 
Controls: 27.6h 
sUC: 4.1h  
rUC: 3.4h 
Controls: 3.2h 
sUC: 5.9h  
rUC: 6.2h 
Controls: 4.9h 
sUC: 34.9h  
rUC: 43.3h 
Controls: 18.2h 
sUC: 9.7h  
rUC: 7.0h 
Controls: 
2.1h 
sUC: 11.6h  
rUC: 18.0h 
Controls: 
14.2h 
  Overnight fast, 
standardized breakfast, 
capsule swallowed 
afterwards 
UC: 20 (relapse n=20, 
remission n=10) 
Controls: 20 (Previous study) 
3D-Transit telemetric 
capsule system (diameter 8 
mm, length 21 mm, 
density 1.6 g/cm3) 
Haase et al 
[23] 
            UC: 2.04h (0.86)  
Controls: 1.51h 
(0.51) 
  UC: 95 
Controls: 115 
Lactulose breath test Rana et al 
[29] 
  UC: 10.59h (7.10) 
Controls: 5.19h (2.13) 
UC: 8.03h (1.38) 
Controls: 7.38h 
(2.04) 
  UC: 12.66h (5.37) 
Controls: 30.68h (21.47) 
  Overnight fast, breakfast, 
SP swallowed  
UC: 5 (mild to moderate) 
Controls: 5 
SmartPill system Bosworth et 
al [27] 
  UC: 4.4h 
Non-IBD patients: 
3.6h 
    Overnight fast, light 
breakfast 4h after 
swallowing the capsule  
UC:23 
aUC:20 
rUC:3 
Non-IBD patients: 125 
Small capsule endoscopy 
studies 
Fischer et al 
[30] 
UC: 24h 
Controls: 26h 
            Overnight fast, capsule 
swallowed  
UC: 5 (4 severe, 1 moderate) 
Controls: 15 
Radiotelemetry capsule Ewe et al 
[25] 
    aUC: 7h (2.3)  
Controls: 6h (2.6) 
  aUC: 7h 
(5.5)  
Controls: 
8h (9.2)  
aUC: 12h 
(6.9)  
Controls: 7h 
(1.4)  
  Standardised ambulatory 
and dietary protocol 
aUC: 4  
Controls: 8 
Radiotelemetry capsule Nugent et al 
[28] 
  UC: 1.6h 
 
UC: 3.4h 
Controls: 3.2h (0.94) 
        Overnight fast, 
standarized breakfast, 
tablet swallowed 
afterwards 
UC:6 (2 active, 4 quiescent) Gamma scintigraphy of a 
radiolabelled tablet with 
cellulose acetate coating 
Hardy et al 
[31] 
Controls: 
Davis et al 
[32] 
 UC:2.7h (0.6) UC:4.0h (1.5)     Light breakfast, tablet 
swallowed afterwards 
UC:5 Gamma scintigraphy of a 
tablet containing 
compressed indium-111-
labelled granules and 
coated with Eudragit L®  
Hardy et al 
[33] 
UC: 8h - >122.5h UC: 1.05h (1.05)  UC: 8.93h (5.90)   UC: 2h - >97.7h 
  
  Overnight fast,swallowed 
capsule, fasting until 
capsule had passed the 
stomach 
UC:6 (severe) Fluoroscopic localization 
of capsule 
Fallingborg 
et al [26] 
aUC: 54.6h (21.8) 
rUC: 53.0h (32.6) 
daUC: 55.0h 
(22.0) 
aUC: 0.81h (0.32) 
rUC: 0.88h (0.52) 
daUC: 0.96h (0.44) 
drUC: 1.13h (0.45) 
    aUC: 4.93h (0.95) 
rUC: 5.28h (1.33) 
daUC: 5.45h 
(1.28) 
Radiolabelled meal aUC: 15 
rUC: 23 
daUC: 23 
drUC: 23 
Hydrogen breath testing, 
radiolabelled meal and 
stool output 
Rao and 
Read [24] 
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drUC: 60.5h 
(42.0) 
Controls: 48.8h 
(22.3) 
Controls: 0.85h (0.37) drUC: 5.23h 
(1.47) 
Controls: 3.82h 
(1.08) 
Controls: 15 
1287 
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Table 2: Colonic pH values in patients with ulcerative colitis. Mean/median (SD/range), treatment with 1sulphasalazine, 2mesalazine, 3olsalazine, n=number of subjects 1288 
pH in controls pH in patients with 
ulcerative colitis in 
remission 
pH in patients with active 
ulcerative colitis 
Special observations Method Reference 
6.7(0.3) (n=7) 4.90(1.3)1 
5.52(1.13)2 
5.51(0.37)3 
(n=6) 
4.7(0.72) 
(n=7) 
 Radiotelemetry capsule Raimundo et al [38] 
Caecum: 5.7 
Rectum: 6.6 
(n=39, previous study) 
 4.63 (1.93) (n=6, very active) Very active disease: 2 
patients transferred for 
surgery during the study, 1 
patient died 
 
Radiotelemetry capsule, fast 
of at least 8h until capsule 
passed the stomach 
Fallingborg et al [26] 
Right: 5.88 
Left: 6.12 
(n=12) 
Right: 7.19 
Left: 6.45 
(n=4) 
Right: 7 
Left: 6.8 
(n=7) 
 Radiotelemetry capsule, 
overnight fast until capsule 
passed the stomach 
Press et al [36] 
Right: 6.5 
Left: 7 
(n=15) 
 Right: 7.4 
Left: 7.6 
(n=5) 
Lowest individual pH values 
were reached in the cecum 
(involved in two of five 
cases), pH did not fall under 
5.5 
Radiotelemetery capsule Ewe et al [25] 
Right: 6.5 (0.6) 
Left: 6.7 (0.1) 
(n=4) 
 Right: 6.7 (0.5) 
Left: 6.7 (0.9) 
(n=8) 
In 2 patients with active 
distal UC a low pH < 5.5 was 
measured 
Radiotelemetry capsule, 
standardised ambulatory and 
dietary protocol 
Nugent et al [28] 
Colon: 7.06 (0.41) 
(n=5) 
 Colon: 6.14 (0.37) 
(n=5, mild to moderate UC) 
 Smart Pill following a 
standardized egg sandwich 
meal and water 
Bosworth et al [27] 
Right: 7.8  
(n=12) 
Right: 6.5 (6.1–7.3) 
(n=12) 
Right: 6.6 (5.5–7.7) 
(n=12) 
 Collection of the ascending 
colon fluid, measurement of 
pH 
Vertzoni et al [37] 
Diakidou et al [39] 
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Table 3: Gastrointestinal transit time in Crohn's disease. Mean/Median (SD), *controls in this study were patients with other diagnosis 1289 
Gastric 
emptying 
time 
Small 
intestinal 
transit time  
Proximal 
colonic 
transit 
time 
Orocecal 
transit time 
Meal Number of 
subjects 
Method Reference 
CD: 0.61h 
(0.75) 
controls*: 
0.58h (0.29) 
CD: 5.62h 
(0.78) 
controls*: 
4.06h (1.39) 
    Overnight 
fast 
CD:19 
Patients with 
other 
diagnosis:178 
Small capsule 
endoscopy studies  
Niv et al [41] 
 Active CD: 
4.2h 
Inactive CD: 
3.1h 
controls*: 
3.6h 
  Overnight 
fast, light 
breakfast 4h 
after 
swallowing 
the capsule  
Active CD: 33 
Inactive CD: 22 
Patients with 
other diagnosis: 
125 
Small capsule 
endoscopy studies 
Fischer et al 
[30] 
      CD: 2.32h 
(0.83) Controls: 
1.51h (0.51) 
  CD:42 
Controls:115 
Lactulose breath 
test 
Rana et al 
[29] 
      CD: 2h 
controls: 1.47h 
  CD:45 
Controls:20 
Lactulose breath 
test 
Tursi et al 
[42] 
CD: 4.0h 
controls: 3.0h 
CD: 2.4h 
controls: 3.0h 
CD: 8.1h 
controls: 
15.5h 
  Fed state CD:6 
Controls:8 
Scintigraphy using 
a capsule 
containing  
111In-labelled 
pellets  
Edsbacker et 
al [40] 
CD: 3.2h 
(0.13) 
controls: 
2.78h (0.11) 
   Fed state CD (inactive): 
26 
Controls: 19 
13C octanoic acid 
breath test 
Nobrega et al 
[46] 
CD: 6.7h (4.2) CD: 3.3h (1.7) 
(n=3) 
  Fed state CD:5 Gamma 
scintigraphy of a 
tablet containing 
compressed 
Hardy et al 
[33] 
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indium-111-
labelled granules 
and coated with 
Eudragit L® 
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Table 4: Effect of IBD on drug interactions with gut bacterial enzymes. Data extracted from [11; 85-88] 1291 
Reaction Enzyme Substrates Bacteria with high enzymatic expression Changes in IBD 
Azoreduction Azoreductase Sulfasalazine, 
prontosil, 
neoprontosil, 
balsalazine, 
olsalazine 
Clostridium sp. Azoreductase activity reduced in CD, 
Clostridium clusters IV and XIVa reduced in 
UC 
Reduction Nitroreductase Nitrazepam Bacteroides fragilis/thetaiotamicron/vulgatus, 
Clostridium perfringens, Eubacterium limosum, 
Escherichia coli, Fusobacterium 
pseudonecrophorum, Peptostreptococcus 
asaccharolyticus 
Bacteroides sp. and Eubacterium sp. 
decreased 
Deglucuronidation β-glucuronidase SN-38G  
(active metabolite of 
irinotecan) 
Bacteroides fragilis/thetaiotamicron/vulgatus, 
Clostridium barati/paraputrificum/perfringens, 
Eubactericum nitrogenes/aerofaciens, 
Peptostreptococcus asaccharolyticus 
Bacteroides sp. and Eubacterium sp. 
decreased  
Thiazole ring-opening  Levamisole Bacteroides and Clostridium sp. (Strongest 
metabolisers) 
Bacteroides sp. and Eubacterium sp. 
decreased, Clostridium clusters IV and XIVa 
reduced in UC 
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Table 5: Gastrointestinal transit time in Celiac disease. Mean/Median (SD) 1293 
Gastric emptying time Small intestinal 
transit time  
Orocecal transit time Meal Number of study 
subjects 
Method Reference 
Celiac disease (children):3.75h 
(1.12) (untreated), 1.46h (0.43) 
(treated) 
Controls: 2.02h (0.7) 
    Overnight fast, 
standard meal 
enriched with 13C 
Celiac disease: 9 
Controls: 9 
13C-octanoic acid breath test Perri et al [92] 
Celiac disease: 5.43h 
Controls: 3.55h 
 
    Overnight fast, test 
meal 
Celiac disease: 16 
Controls: 24 
Ultrasonographic emptying 
studies 
Benini et al [98] 
Celiac disease: 3.38h (0.53) 
Controls: 2.22h (0.25) 
  Overnight fast, test 
meal 
Celiac disease: 9 
Controls: 9 
Ultrasonographic emptying 
studies 
Bardella et al [99] 
    Celiac disease 
(untreated): 4.05h 
(0.17) 
Controls: 1.95h (0.1) 
Fasting period of at 
least 12h 
Celiac disease: 16 
Controls: 20 
Hydrogen breath test Battaglia et al [95]  
    Celiac disease: 2.13h 
Controls: 1.01h 
Overnight fast, test 
meal 
Celiac disease: 25 
Controls: 7 
Hydrogen breath test Spiller et al [96] 
Celiac disease: 0.51h (0.37)  
Controls: 0.73h (0.81) 
Celiac disease: 
4.20h (1.12) 
Controls: 4.08h 
(1.47) 
  Bowel cleansing 
day before, fasting 
since midnight, 
drinking 2h/ eating 
4h after capsule 
ingestions 
Celiac disease: 30 
Controls: 30 
Small bowel PillCam® Urgesi et al [100] 
1294 
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Figure captions 1295 
Figure 1: Gastrointestinal pH profile in patients with Ulcerative Colitis (x: mean/median 1296 
values, open circles: single values) 1297 
Figure 2: Gastrointestinal pH profile in Crohn's disease (x: mean/median values) 1298 
Figure 3: pH values in the small intestine of SBS patients (x: mean value, blue line: mean 1299 
value controls, red line: mean value SBS patients) 1300 
Figure 4: Overview of changes in gastrointestinal diseases compared to healthy state 1301 
Figure 5: in vitro dissolution/release models for modified release dosage forms; a: Klein et al 1302 
[190], b: Schellekens et al [187], c: Ahmed and Ayres [189], d: Goyanes et al [188] 1303 
 1304 
 1305 
  1306 
60 
 
 1307 
 1308 
 1309 
61 
 
 1310 
  1311 
62 
 
 1312 
 1313 
 1314 
63 
 
 1315 
 1316 
64 
 
 1317 
